We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
GR 64349 peptide acts as an agonist of neurokinin (NK2) receptor, which reduces NK2 response to kainate and AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), but not to NMDA (N-methyl-D-aspartate)
CAT No: R0803
CAS No: 137593-52-3
Synonyms/Alias: GR 64349;137593-52-3;136548-07-7;(3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(3R)-1-[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-2-oxopyrrolidin-3-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-[[(2S)-2,6-diaminohexanoyl]amino]-4-oxobutanoic acid;3-Lys-8-gly-R-lactam-9-leu-neurokinin A (3-10);Neurokinin A (3-10), lys(3)-gly(8)-R-lactam-leu(9)-;Neurokinin A (3-10), lysyl(3)-glycyl(8)-R-lactam-leucine(9)-;(3R-(1(S*(S*)),3R*))-L-Lysyl-L-alpha-aspartyl-L-seryl-L-phenylalanyl-N-(1-(1-(((1-(aminocarbonyl)-3-(methylthio)propyl)amino)carbonyl)-3-methylbutyl)-2-oxo-3-pyrrolidinyl)-L-valinamide;L-Valinamide, L-lysyl-L-alpha-aspartyl-L-seryl-L-phenylalanyl-N-(1-(1-(((1-(aminocarbonyl)-3-(methylthio)propyl)amino)carbonyl)-3-methylbutyl)-2-oxo-3-pyrrolidinyl)-, (3R-(1(S*(S*)),3R*))-;DA-63889;MS-31721;G12420;
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C42H68N10O11S |
M.W/Mr. | 921.1 |
Sequence | KDSFVGLM(Modifications: Leu-7 = R-γ-lactam-Leu, Met-8 = C-terminal amide) |
Labeling Target | NK-2 tachykinin receptor |
Application | GR 64349 is a potent and selective agonist at the NK-2 tachykinin receptor, which Initiates changes in the colon, intestine and spinal cord. |
Appearance | White lyophilised solid |
Purity | >98% (or refer to the Certificate of Analysis) |
Activity | Agonist |
InChI | InChI=1S/C42H68N10O11S/c1-23(2)19-32(40(61)46-27(35(45)56)15-18-64-5)52-17-14-28(42(52)63)47-41(62)34(24(3)4)51-38(59)29(20-25-11-7-6-8-12-25)49-39(60)31(22-53)50-37(58)30(21-33(54)55)48-36(57)26(44)13-9-10-16-43/h6-8,11-12,23-24,26-32,34,53H,9-10,13-22,43-44H2,1-5H3,(H2,45,56)(H,46,61)(H,47,62)(H,48,57)(H,49,60)(H,50,58)(H,51,59)(H,54,55)/t26-,27-,28+,29-,30-,31-,32-,34-/m0/s1 |
InChI Key | HVUNRXRFMQDMBO-ICQHUDCBSA-N |
Isomeric SMILES | CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)N1CC[C@H](C1=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)N |
BoilingPoint | 1342.8ºC at 760mmHg |
Melting Point | N/A |
1. Implications of ligand-receptor binding kinetics on GLP-1R signalling
3. High fat diet and GLP-1 drugs induce pancreatic injury in mice
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.